Vonoprazan: First Global Approval

@article{GarnockJones2015VonoprazanFG,
  title={Vonoprazan: First Global Approval},
  author={Karly P. Garnock-Jones},
  journal={Drugs},
  year={2015},
  volume={75},
  pages={439-443}
}
Vonoprazan (Takecab®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

TAK - 438 vs . lansopra - zole 15 mg for secondary prevention of peptic ulcers associated with low - dose aspirin therapy : results of a phase 3 trial ( abstract no . Tu 1055 )

  • T Kawai, K Ashida, Y Mizokami
  • Gastroenterology
  • 2014

submits a new drug application for TAK-438 in Japan for the treatment of acid-related diseases

  • Takeda. Takeda
  • (media release)
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…